PHAT
Phathom Pharmaceuticals Inc
7.30$
+1.7%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Phathom Pharmaceuticals Inc (PHAT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -1.9 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.2 | -0.2 | -0.3 | -0.3 | -0.8 | -5.2 | -7.1 | -23 | -11 | -9.3 | -21 | -28 | -50 | -28 | -29 | -41 | -45 | -26 | -35 | -41 | -40 | -22 | -32 | -44 | -69 | -71 | -64 | -63 | -85 | -63 | -14 | -5.0 | -16 | -1.9 | -37 | |
| – | – | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.5 | |
| – | – | – | – | – | 0.0 | 0.0 | 0.3 | 0.6 | 0.8 | 2.1 | 2.4 | 3.8 | 4.2 | 4.4 | 4.3 | 5.8 | 5.9 | 5.8 | 6.7 | 7.0 | 7.3 | 6.1 | 25 | 5.6 | 6.1 | 5.6 | 6.7 | 5.5 | 8.3 | 9.3 | 5.6 | 5.5 | 6.7 | 27 | |
| – | – | 0.0 | 0.0 | 0.0 | 60 | 60 | 85 | 0.5 | 0.8 | 2.2 | 2.5 | 3.8 | 4.4 | 4.7 | 5.3 | 7.2 | 7.0 | 7.0 | 13 | 8.7 | 14 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 0.0 | 0.2 | 0.4 | -0.2 | 0.5 | -10 | 8.0 | 11 | 11 | 23 | -20 | 3.3 | 0.3 | -12 | -12 | 15 | 2.7 | 0.2 | -16 | 4.4 | -2.4 | 0.7 | -7.0 | -0.6 | 1.4 | -9.0 | -8.9 | -6.0 | -1.6 | 4.0 | 1.5 | 2.6 | 6.7 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.7 | 0.1 | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.1 | 0.1 | 0.4 | 0.1 | 0.4 | 0.2 | 0.0 | 0.9 | 0.5 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.2 | |
| – | – | -13 | -13 | 0.0 | -25 | 0.0 | -0.1 | -0.7 | -0.1 | -0.2 | -0.1 | -0.2 | 0.0 | 0.0 | -0.1 | -0.1 | -0.4 | -0.1 | -0.4 | -0.2 | 0.0 | -0.9 | -0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | -0.1 | 0.0 | -0.2 | |
| – | – | 0.0 | 0.0 | – | – | -1.3 | 191 | – | – | – | – | 0.4 | – | – | – | – | – | 25 | – | 14 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | 0.3 | 0.7 | 25 | 25 | 25 | 25 | 25 | – | – | 43 | 43 | 43 | 43 | 95 | 95 | 95 | – | – | – | – | – | – | – | – | 0.0 | 25 | 0.0 | 0.0 | 0.0 | 0.0 | -56 | 0.0 | -56 | |
| 0.3 | 0.3 | 0.3 | 1.1 | 0.0 | 113 | -1.3 | 193 | 25 | 89 | 25 | 89 | 0.4 | 0.1 | 44 | 0.2 | 95 | 95 | 25 | 142 | 14 | 142 | 0.0 | 212 | 9.9 | 25 | 122 | 26 | 0.0 | 0.1 | -0.3 | -0.1 | 67 | 3.6 | 70 | |
| 0.1 | 0.1 | 0.0 | 0.7 | -0.8 | 83 | -8.4 | 169 | 13 | -9.4 | -21 | 61 | -50 | -28 | 15 | -41 | -45 | 69 | -11 | -41 | -26 | 119 | -33 | 168 | -59 | -46 | 58 | -37 | -85 | -63 | -14 | -5.2 | 51 | 1.6 | 33 | |
| -0.2 | -0.2 | -0.3 | -0.3 | -0.8 | -5.2 | -7.1 | -23 | -12 | -9.4 | -21 | -28 | -50 | -28 | -29 | -42 | -45 | -26 | -35 | -41 | -40 | -22 | -33 | -44 | -69 | -71 | -63 | -63 | -85 | -63 | -14 | -4.9 | -16 | -2.0 | -37 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.